In March 2007, Calistoga Pharmaceuticals completed a Series A venture financing for $21 million led by Frazier Healthcare Ventures and also including Alta Partners, Three Arch Partners, and Amgen Ventures. Proceeds from this financing will primarily be used to build out corporate and research operations, complete clinical proof of concept studies and for the advance the company’s product candidates into clinical studies.

About Frazier Healthcare Ventures
Founded in 1991 and with more than $1.2 billion of capital under management, Frazier Healthcare is one of the nation's leading providers of venture and growth equity capital to emerging healthcare companies. Having invested in more than 113 emerging healthcare companies to date, Frazier Healthcare is well known for its depth of experience and the technical expertise of its investment team. This experience encompasses product development and launch, clinical trial implementation and design, industry operating experience, academic research and clinical practice. Partnering with Frazier Healthcare provides access to capital and an unparalleled breadth of relevant healthcare industry experience. For more information about Frazier Healthcare Ventures go to: www.frazierhealthcare.com.

About Alta Partners
Alta Partners is a San Francisco-based venture capital firm focused on life sciences investing. Founded in 1996, the firm currently manages $2 billion in committed capital through eight venture fund programs. Alta invests in life sciences companies across the development continuum, from company formation to later-stage opportunities, and has funded more than 110 companies in the sector to date. For more information about Alta Partners go to: www.altapartners.com.

About Three Arch Partners
Three Arch Partners was formed in 1993 to provide young companies with access to relevant clinical and business resources, as well as capital. Three Arch Partners has helped create, build, and fund more than 100 healthcare companies. The investment focus is on opportunities in medical devices and healthcare services, as well as biotechnology and information technology. The partnership manages over $1 billion in capital. For more information about Three Arch Partners go to: www.threearchpartners.com.

About Amgen Ventures
Amgen Ventures, formed in 2004, is a corporate venture capital fund designed to provide emerging biotechnology companies with resources to develop pioneering discoveries focused on human therapeutics. Amgen Ventures reflects Amgen’s commitment to helping patients. The fund can offer early stage companies access to Amgen’s extensive capabilities while providing Amgen with insight into external research innovations that may pave the way for future collaborations. For more information about Amgen Ventures go to: www.amgen.com/partners/amgen_ventures.html.